MedTrace Logo

Study of GBT009 for Treatment of Incisional Wounds Following Breast Reconstruction Surgery

NCT01053897 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2013-10-24

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to assess whether intradermal injections of GBT009 along full thickness incisions following surgery results in an improvement in scar appearance.

Conditions

  • Scar Formation

Interventions

BIOLOGICAL

GBT009

Intradermal Injection following surgery

BIOLOGICAL

Placebo

Intradermal Injection following surgery

Sponsors & Collaborators

  • Garnet BioTherapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Garnet Study Manager · Garnet BioTherapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01053897 on ClinicalTrials.gov